You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study ☆
|
|---|---|
| Published in |
Annals of Oncology, October 2023
|
| DOI | 10.1016/j.annonc.2023.10.117 |
| Pubmed ID | |
| Authors |
A. Passaro, J. Wang, Y. Wang, S.-H. Lee, B. Melosky, J.-Y. Shih, J. Wang, K. Azuma, O. Juan-Vidal, M. Cobo, E. Felip, N. Girard, A.B. Cortot, R. Califano, F. Cappuzzo, S. Owen, S. Popat, J.-L. Tan, J. Salinas, P. Tomasini, R.D. Gentzler, W.N. William, K.L. Reckamp, T. Takahashi, S. Ganguly, D.M. Kowalski, A. Bearz, M. MacKean, P. Barala, A.B. Bourla, A. Girvin, J. Greger, D. Millington, M. Withelder, J. Xie, T. Sun, S. Shah, B. Diorio, R.E. Knoblauch, J.M. Bauml, R.G. Campelo, B.C. Cho, MARIPOSA-2 Investigators |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 29% |
| India | 2 | 29% |
| United Kingdom | 1 | 14% |
| Unknown | 2 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 4 | 57% |
| Members of the public | 3 | 43% |
Mendeley readers
The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 52 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 9 | 17% |
| Unspecified | 8 | 15% |
| Researcher | 5 | 10% |
| Student > Master | 3 | 6% |
| Student > Doctoral Student | 2 | 4% |
| Other | 5 | 10% |
| Unknown | 20 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 25% |
| Unspecified | 8 | 15% |
| Biochemistry, Genetics and Molecular Biology | 5 | 10% |
| Chemical Engineering | 1 | 2% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Other | 2 | 4% |
| Unknown | 22 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 445. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 March 2024.
All research outputs
#62,799
of 25,443,857 outputs
Outputs from Annals of Oncology
#29
of 7,862 outputs
Outputs of similar age
#1,091
of 357,948 outputs
Outputs of similar age from Annals of Oncology
#1
of 170 outputs
Altmetric has tracked 25,443,857 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,862 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.6. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 357,948 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 170 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.